Cancer Survival And Symptom Trials May Be "Ideal Drug Package" - Pazdur
Executive Summary
Submission of one cancer survival trial and one symptom trial for approval of oncologic agents would be considered optimal by FDA, Oncologic Drug Products Division Director Richard Pazdur, MD, said.
You may also be interested in...
FDA Reviewing Cancer Trial Endpoints, Oncology Director Pazdur Tells ASCO
FDA's Division of Oncologic Drug Products will conduct an internal review of regulatory endpoints for cancer trials, division Director Richard Pazdur, MD, said May 13 during the American Society of Clinical Oncology annual meeting in San Francisco.
Maxamine Melanoma Liver Subset Needs More Focused Study - FDA Cmte.
Maxim would have to conduct a new, larger study focused solely on metastatic melanoma that has spread to the liver in order to support approval of Maxamine, FDA's Oncologic Drugs Advisory Committee suggested Dec. 13.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011